What does this research mean for the field?

Etelcalcetide provides significantly greater, more sustained, and more consistent long-term (24-month) parathyroid hormone suppression compared to cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare the long-term effectiveness of etelcalcetide versus cinacalcet in managing secondary hyperparathyroidism in hemodialysis patients over 24 months.

August 30, 2026Journal of Clinical MedicineOpen Access

Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up

View Full Paper

Ask AI

Bookmark

To compare the long-term effectiveness of etelcalcetide versus cinacalcet in managing secondary hyperparathyroidism in hemodialysis patients over 24 months.
Conducted a multicenter retrospective study screening 457 hemodialysis patients across five centers in Türkiye.
Applied propensity score matching on age, sex, hemodialysis vintage, and baseline intact parathyroid hormone (iPTH) to yield balanced cohorts (21 vs. 21 at 12 months; 14 vs. 14 at 24 months).
Assessed percentage change in iPTH (%ΔPTH), KDIGO target attainment, sustained response, and mineral metabolism parameters over 24 months of follow-up.
Etelcalcetide demonstrated significantly greater iPTH reduction than cinacalcet at 12 months (%ΔPTH: −50.5 ± 25.6% vs. −29.7 ± 40.6%; p = 0.047), with effect sizes widening at 24 months (Cohen’s d: −0.612 to −0.779).
Sustained response (≥30% iPTH reduction at 12 and 24 months) was significantly higher with etelcalcetide (78.6% vs. 28.6%; p = 0.021), as was deep response (≥75% reduction) at 24 months (57.1% vs. 14.3%; p = 0.046).
At 24 months, etelcalcetide achieved lower serum calcium (p = 0.015), lower calcium–phosphate product (p = 0.023), superior phosphate target attainment (85.7% vs. 28.6%; p = 0.004), and nearly three-fold lower response variability (CV: 42% vs. 151%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Multicenter cohort study reveals superior parathyroid hormone suppression with etelcalcetide over cinacalcet in hemodialysis, indicating improved long-term mineral metabolism control.

Cite This Study

Öztürk et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0696c1a8fb52e79c8dc https://doi.org/10.3390/jcm15176656

View Full Paper

Ask AI

Bookmark

Implication

Multicenter cohort study reveals superior parathyroid hormone suppression with etelcalcetide over cinacalcet in hemodialysis, indicating improved long-term mineral metabolism control.

Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up

Key Points

Discussion

Implication

Cite This Study

Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider